表紙
市場調查報告書
商品編碼
997007

乾燥症(修格蘭氏症候群)治療藥的全球市場(2021年∼2025年)

Global Sjogrens Syndrome Therapeutics Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

乾燥症(修格蘭氏症候群)治療藥的市場規模在2021年∼2025年間預測將以4%的年複合成長率推移,並成長到2億8,768萬美元。

乾燥症(修格蘭氏症候群)治療藥的市場規模相關之本報告提供整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

市場成長的主要因素有>強大的藥品生產線,乾燥症(修格蘭氏症候群)的高得病率和發生率以及產品計劃和預期的批准。尤其是強大的製藥渠道有望促進市場增長。

本報告提供乾燥症(修格蘭氏症候群)治療藥市場調查,提供市場概要,市場規模,市場預測,客戶形勢,各類型·各地區的分析,再加上業者情勢和供應商分析等資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模(2020年)
  • 市場預測:從2020年∼2025年的預測

波特的五力分析

各類型的市場區隔

  • 市場區隔
  • 各類型比較
  • 原發性乾燥症(修格蘭氏症候群):市場規模與預測(2020年∼2025年)
  • 二次乾燥症(修格蘭氏症候群):市場規模與預測(2020年∼2025年)
  • 各類型的市場機會

客戶形勢

各地區形勢

  • 各地區市場區隔
  • 各地區比較
  • 北美:市場規模與預測(2020年∼2025年)
  • 歐洲:市場規模與預測(2020年∼2025年)
  • 亞洲:市場規模與預測(2020年∼2025年)
  • 其他地區:市場規模與預測(2020年∼2025年)
  • 主要國家
  • 地區的市場機會
  • 市場促進因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • ADVANZ PHARMA Corp. Ltd.
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.

附錄

目錄
Product Code: IRTNTR70328

Technavio has been monitoring the sjogrens syndrome therapeutics market and it is poised to grow by $ 287.68 mn during 2021-2025 progressing at a CAGR of 4% during the forecast period. Our report on sjogrens syndrome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the strong drug pipeline, high prevalence and incidence of Sjogren's syndrome, and initiatives and expected approvals of products. In addition, strong drug pipeline is anticipated to boost the growth of the market as well.

The sjogrens syndrome therapeutics market analysis includes type segment and geographical landscape.

Technavio's sjogrens syndrome therapeutics market is segmented as below:

By Type

  • primary Sjogren's syndrome
  • secondary Sjogren's syndrome

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing development of biologics as one of the prime reasons driving the sjogrens syndrome therapeutics market growth during the next few years. Also, increasing diagnostic tests and biomarkers and rising number of awareness programs will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on sjogrens syndrome therapeutics market covers the following areas:

  • Sjogrens syndrome therapeutics market sizing
  • Sjogrens syndrome therapeutics market forecast
  • Sjogrens syndrome therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading sjogrens syndrome therapeutics market vendors that include AbbVie Inc., ADVANZ PHARMA Corp. Ltd., Biogen Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Co. Ltd., Hikma Pharmaceuticals Plc, Johnson & Johnson, Novartis AG, Sanofi SA, and Sun Pharmaceutical Industries Ltd.. Also, the sjogrens syndrome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Primary Sjogren's syndrome - Market size and forecast 2020-2025
  • Secondary Sjogren's syndrome - Market size and forecast 2020-2025
  • Market opportunity by Type

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • ADVANZ PHARMA Corp. Ltd.
  • Biogen Inc.
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • Hikma Pharmaceuticals Plc
  • Johnson & Johnson
  • Novartis AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Customer landscape
  • 22: Impact of drivers and challenges
  • 23: Vendor landscape
  • 24: Landscape disruption
  • 25: Industry risks
  • 26: Vendors covered
  • 27: Market positioning of vendors
  • 28: AbbVie Inc. - Overview
  • 29: AbbVie Inc. - Business segments
  • 30: AbbVie Inc. - Key offerings
  • 31: AbbVie Inc. - Key customers
  • 32: AbbVie Inc. - Segment focus
  • 33: ADVANZ PHARMA Corp. Ltd. - Overview
  • 34: ADVANZ PHARMA Corp. Ltd. - Business segments
  • 35: ADVANZ PHARMA Corp. Ltd. - Key offerings
  • 36: ADVANZ PHARMA Corp. Ltd. - Key customers
  • 37: ADVANZ PHARMA Corp. Ltd. - Segment focus
  • 38: Biogen Inc. - Overview
  • 39: Biogen Inc. - Business segments
  • 40: Biogen Inc. - Key offerings
  • 41: Biogen Inc. - Key customers
  • 42: Biogen Inc. - Segment focus
  • 43: Bristol-Myers Squibb Co. - Overview
  • 44: Bristol-Myers Squibb Co. - Product and service
  • 45: Bristol-Myers Squibb Co. - Key offerings
  • 46: Bristol-Myers Squibb Co. - Key customers
  • 47: Bristol-Myers Squibb Co. - Segment focus
  • 48: Daiichi Sankyo Co. Ltd. - Overview
  • 49: Daiichi Sankyo Co. Ltd. - Business segments
  • 50: Daiichi Sankyo Co. Ltd. - Key offerings
  • 51: Daiichi Sankyo Co. Ltd. - Key customers
  • 52: Daiichi Sankyo Co. Ltd. - Segment focus
  • 53: Hikma Pharmaceuticals Plc - Overview
  • 54: Hikma Pharmaceuticals Plc - Business segments
  • 55: Hikma Pharmaceuticals Plc - Key offerings
  • 56: Hikma Pharmaceuticals Plc - Key customers
  • 57: Hikma Pharmaceuticals Plc - Segment focus
  • 58: Johnson & Johnson - Overview
  • 59: Johnson & Johnson - Business segments
  • 60: Johnson & Johnson - Key offerings
  • 61: Johnson & Johnson - Key customers
  • 62: Johnson & Johnson - Segment focus
  • 63: Novartis AG - Overview
  • 64: Novartis AG - Business segments
  • 65: Novartis AG - Key offerings
  • 66: Novartis AG - Key customers
  • 67: Novartis AG - Segment focus
  • 68: Sanofi SA - Overview
  • 69: Sanofi SA - Business segments
  • 70: Sanofi SA - Key offerings
  • 71: Sanofi SA - Key customers
  • 72: Sanofi SA - Segment focus
  • 73: Sun Pharmaceutical Industries Ltd. - Overview
  • 74: Sun Pharmaceutical Industries Ltd. - Business segments
  • 75: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 76: Sun Pharmaceutical Industries Ltd. - Key customers
  • 77: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 78: Currency conversion rates for US$
  • 79: Research Methodology
  • 80: Validation techniques employed for market sizing
  • 81: Information sources
  • 82: List of abbreviations